Overview
Penile and vulvar cancers—though relatively rare—are seeing a concerning rise in certain populations, partly due to misinformation and lack of awareness about the human papillomavirus (HPV). HPV is a sexually transmitted infection responsible for nearly all cases of cervical cancer and a significant portion of penile, vulvar, anal, and oropharyngeal cancers. Misinformation about the HPV vaccine, under-screening, and social stigma have created barriers to prevention and early detection, especially in conservative or underserved communities.

Causes

• HPV Infection: High-risk HPV strains (especially types 16 and 18) are directly linked to the development of penile and vulvar cancers.
• Lack of Vaccination: Vaccine hesitancy fueled by myths about safety, morality, or fertility prevents widespread immunization.
• Poor Sexual Health Education: Misinformation about HPV transmission and cancer risks limits public understanding.
• Delayed Diagnosis: Stigma around genital health and lack of routine screenings delay detection of precancerous lesions.
• Immunosuppression: HIV-positive individuals and transplant recipients have higher rates of persistent HPV infection and related cancers.

HPV Misinformation Factors

• Myths About Vaccine Safety: False claims about infertility, autoimmune disease, or behavioral changes discourage uptake.
• Sexual Stigma: Cultural or religious views may hinder open discussion of HPV as a sexually transmitted infection.
• Lack of Male Inclusion: The misconception that HPV vaccination is only for girls leaves boys unprotected.
• Social Media Misinformation: Online platforms can amplify anti-vaccine rhetoric and pseudoscience.

Symptoms

• Penile Cancer:
  • Lesions, ulcers, or growths on the penis
  • Pain, discharge, or bleeding
  • Swelling in the groin or penile tissue
• Vulvar Cancer:
  • Persistent itching, pain, or burning in the vulvar area
  • Visible lumps, sores, or color changes
  • Pain during urination or intercourse

Diagnosis

• Clinical Examination: Visual inspection and physical examination of any suspicious lesions.
• Biopsy: Required for definitive diagnosis and staging.
• HPV DNA Testing: Identifies high-risk HPV subtypes.
• Imaging (e.g., MRI, CT): Used for staging and assessing lymph node involvement.

Prevention

• HPV Vaccination:
  • Safe and effective for preventing high-risk HPV infections and related cancers.
  • Recommended for all genders, ideally starting at ages 9–12, with catch-up vaccination up to age 26 (and sometimes older).
• Safe Sexual Practices: Condom use and limiting sexual partners reduce HPV transmission risk.
• Regular Checkups: Routine pelvic exams and genital skin checks for early detection.
• Public Education: Campaigns to combat myths and promote vaccine acceptance, especially in high-risk communities.

Treatment

• Surgical Removal: Early-stage cancers may be treated with localized excision or laser therapy.
• Radiation and Chemotherapy: Used in more advanced cases or when surgery isn’t feasible.
• Targeted Therapies and Immunotherapy: Emerging treatments for metastatic or recurrent disease.
• Supportive Care: Psychosocial support for stigma, sexual health, and body image concerns.

Prognosis
When detected early, both penile and vulvar cancers have good outcomes with treatment. However, advanced cases can lead to disfigurement, reduced quality of life, or mortality. Improved education and vaccination can prevent the vast majority of cases.

Global Trends

• Rising incidence in regions with low HPV vaccination coverage, especially in rural, conservative, or low-income populations.
• Male HPV-related cancer rates are increasing due to delayed public health focus on male vaccination.
• WHO’s 2030 strategy for cervical cancer elimination also emphasizes broader HPV vaccination to curb related cancers.